The clinical importance of testosterone in men with type 2 diabetes
|
|
- Rosanna Gordon
- 5 years ago
- Views:
Transcription
1 22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely measured in diabetic patients. Various studies have highlighted the high prevalence of low total and free testosterone (late-onset hypogonadism or testosterone deficiency syndrome) in men with type 2 diabetes and demonstrated links with visceral adiposity, insulin resistance, HbA 1c, and symptoms of hypogonadism such as erectile dysfunction (ED) and low sexual desire. 1 4 Insulin resistance and visceral obesity are important features of type 2 diabetes 1 and are established markers of cardiovascular risk. An inverse relationship has been established between testosterone levels and insulin concentration in healthy men. 5 Low testosterone has been found to predict insulin resistance and later appearance of metabolic syndrome and type 2 diabetes, as well as a significant increase in all-cause and cardiovascular mortality in long-term studies. 6,7 GUIDELINE RECOMMENDATIONS Current expert guidelines recommend that patients with symptoms of overt hypogonadism and total testosterone levels below 8nmol/l (free testosterone 180pmol/l) should be treated with testosterone replacement therapy, 8,9 but there is no UK policy for screening at-risk populations such as those with type 2 diabetes. The NICE guideline on Overt hypogonadism TT <8nmol/l Figure 1. Investigation and treatment of testosterone deficiency syndrome 9 Dr G.I. Hackett, MD, FRCPI, MRCGP, Consultant in Sexual Medicine, Good Hope Hospital, Sutton Coldfield, West Midlands Signs and symptoms of testosterone deficiency Take morning serum sample for determination of TT and SHBG (between and 11.00, when testosterone is at its peak) Borderline hypogonadism TT 8 12nmol/l Retest TT LH/FSH, prolactin, SHBG, calculate free testosterone Confirmed TT <8nmol/l or 8 12nmol/l with signs and symptoms, with normal LH/FSH and prolactin Exclude occult prostate cancer (DRE and PSA) and check baseline haematocrit Initiate TRT Monitor Abnormal LH/FSH and prolactin Refer Not hypogonadism TT >12nmol/l Normal free testosterone >250pmol/l (72pg/ml) Other causes TT, Total testosterone; SHBG, sex-hormone-binding globulin; LH, luteinising hormone; FSH, follicle-stimulating hormone; DRE, digital rectal examination; PSA, prostate-specific antigen; TRT, testosterone replacement therapy
2 23 management of type 2 diabetes 10 recommends annual assessment, appropriate investigation and treatment of all men with type 2 diabetes for ED. ED is recognised as an independent predictor of coronary risk, especially in men with type 2 diabetes. 11 The current guidelines of the British Society for Sexual Medicine and the European Association of Urology list testosterone measurement as mandatory in all men presenting with ED, as it represents a potentially treatable risk factor. 8,9 They recommend that men with a total testosterone of less than 8nmol/l should be treated and that those between 8 and 12nmol/l should be considered for treatment according to symptoms (Figure 1). An Endocrine Society task force in 2006 recognised the link between hypogonadism and type 2 diabetes and recommended physicians to consider measuring testosterone in all men with type 2 diabetes. 12 In their public health guidance 15, 13 NICE also recommended that it should be a high priority to identify populations at risk of early death from coronary heart disease. Men with type 2 diabetes, ED and hypogonadism are surely an important group for active intervention. The current GP contract is associated with strict targets in type 2 diabetes linked with the Quality and Outcomes Framework (QOF) and GP performance and payment. CONSEQUENCES OF LOW TESTOSTERONE The association of low testosterone with type 2 diabetes has been established in many studies. Three large long-term studies, including the Massachusetts Male Ageing Study 14 and the Multiple Risk Factor Intervention Trial, 15 suggest that low total testosterone, free testosterone and sex-hormone-binding globulin (SHBG) are independent risk factors for later development of type 2 diabetes. The Third National Health and Nutrition Survey 16 demonstrated that men in the lowest tertiles of free testosterone and bioavailable BOX 1. Signs and symptoms associated with low testosterone 1 Reduced sexual desire and erectile quality Diminished energy Reduced vitality or wellbeing Increased fatigue Depressed mood Impaired cognition Decreased muscle mass and strength Diminished bone density Obesity Anaemia testosterone, but not total testosterone, were four times more likely to develop type 2 diabetes than those in the third tertile, after adjustment for adiposity, age, race and ethnicity. Kapoor et al. 1 showed strong associations between symptoms and biochemical hypogonadism. Hackett et al. 17 showed clear links between low testosterone and increased body mass index (BMI), waist circumference, HbA 1c and ED. ED is the most common symptom seen in men with type 2 diabetes (50 75 per cent) 8,11 in most series, as assessed by the Sexual Health Inventory for Men. 18 Other symptoms associated with low testosterone are listed in Box 1. 1 Unfortunately, many press articles have chosen to concentrate on these issues under the guise of the non-existent male menopause, to the detriment of evidence-based patient care. The current GP contract puts strong emphasis on type 2 diabetes as a target priority and rewards GPs financially for achieving quality targets in areas that include BMI, waist circumference, HbA 1c, blood pressure, total cholesterol, prescribing of angiotensin-converting enzyme inhibitors, and eye and foot assessment. Hackett et al. 17 suggest strong associations between total testosterone and BMI, waist circumference, HbA 1c and SHBG (Figures 2 and 3). Patients with low total testosterone, free testosterone and bioavailable testosterone 19 will not only be subject to the potentially greater risk associated with these levels, but are significantly more likely to fall outside QOF targets and result in underperformance. The current top HbA 1c target of 7.5 per cent is not being achieved by 50 per cent of men in the low testosterone group versus 33 per cent in the normal group. As this target is to be reduced to 7.0 per cent for 2009/10 and possibly 6.5 per cent in line with NICE guidance, 10,20 these new targets may be very difficult to achieve with current strategies, particularly as conversion to insulin therapy is associated with weight gain. ERECTILE DYSFUNCTION: THE IMPORTANT DRIVER FOR TREATMENT Testosterone is not measured routinely in UK and European diabetic practice, in spite of current guidelines suggesting that it should always be measured in the 75 per cent of men with type 2 diabetes who suffer from ED Wu et al. 21 highlighted the strong associations of late-onset hypogonadism with type 2 diabetes and the importance of ED, reduced libido and absence of spontaneous erections in making the diagnosis. Failure to measure testosterone results in considerable waste of resources, as response rates to phosphodiesterase type 5 inhibitors (PDE5Is) are low in men with type 2 diabetes and lateonset hypogonadism. Testosterone supplementation has been clearly shown to enhance responsiveness, and in per cent of cases 12 resolves the problem as sole therapy. Improvement of libido and orgasm can be equally important in men with type 2 diabetes. Once testosterone deficiency syndrome is diagnosed in men presenting with ED, the patient expectation is that it should be treated, and this fact alone is the TRENDS IN UROLOGY & MEN S HEALTH OCTOBER/NOVEMBER
3 24 BMI (kg/m 2 ) major reason for the significant increase in NHS prescriptions for testosterone over the past five years. The usual explanation for not measuring testosterone stated in review articles is the presumption that low total testosterone is a consequence of visceral obesity and ageing, or that the fall in SHBG associated with obesity in type 2 diabetes will result in adequate levels of free testosterone, yet the studies suggest that prevalence of testosterone deficiency is even greater if assessed by free testosterone A more realistic explanation is that the target-based management of type 2 Waist (cm) Figure 2. Association between total testosterone (TT, nmol/l), body mass index (BMI) and waist circumference 17 HbA 1c (%) diabetes is already an onerous workload for clinicians and that routine questioning about ED and associated testosterone estimation will lead to considerable additional workload, without resources or remuneration. When ED is detected, it will usually have to be managed, with associated prescribing costs and possible referral implications. The prevalence of ED in type 2 diabetes is around 75 per cent and is strongly associated with low free testosterone. Romeo et al. 22 and Rhoden et al. 23 described a linear relationship with HbA 1c in men with type 2 diabetes. SHGB (nmol/l) Figure 3. Association between total testosterone (TT, nmol/l), HbA 1c and sex-hormonebinding globulin (SHBG) 17 METABOLIC EFFECTS OF TESTOSTERONE SUPPLEMENTATION The important question is whether restoration of testosterone to normal range will reduce cardiovascular risk and improve diabetes control in terms of reduced HbA 1c, insulin resistance and visceral adiposity. Interventional studies have shown a consistent beneficial effect with testosterone therapy on insulin resistance, visceral adiposity, sexual function and physical symptoms. Kapoor et al. 24 treated 24 patients with testosterone undecanoate 200mg every two weeks for a 12-week period. They found significant improvement in insulin resistance as measured by homeostasis model assessment-insulin resistance, total cholesterol but not blood pressure. The same authors also found beneficial effects on adipocytokines and C-reactive protein levels. 25 In the IPASS study, 26 the largest published series of treatment of over 700 patient years with long-term depot testosterone undecanoate, there was a mean 5cm reduction in waist circumference, marked improvement in energy levels, mood, concentration, libido and erectile function. The rate of ED fell from 61 to 25 per cent and the response rate to PDE5Is increased from 37 to 60 per cent. 26 There was a minor normalisation of prostate-specific antigen, but no cases of prostate cancer in the treated group. The metabolic effects of testosterone are enhanced by lifestyle change. 27 Recent meta-analyses have consistently shown no link between testosterone supplementation and prostate cancer. 28 CONCLUSIONS NICE guidance on type 2 diabetes recommends that men should be asked annually about ED, and the prevalence of ED in type 2 diabetes is clearly established as being around 75 per cent. There are important implications that arise from this
4 25 single recommendation. All ED guidelines recommend testosterone evaluation in all men with ED, 11 and at least 40 per cent of men with type 2 diabetes will have testosterone levels that guidelines suggest should be treated. The Endocrine Society recommends measurement of testosterone in all men with type 2 diabetes. Low response rates to ED medication in men with low testosterone means considerable waste, as low testosterone has been shown to be a major reason for non-response. Once men with type 2 diabetes are asked about ED, following evidence-based guidelines, many will be diagnosed with low testosterone and this will demand testosterone supplementation as optimal treatment for important troublesome symptoms. The current NHS care pathway of urologist management of ED and associated testosterone deficiency syndrome is not helpful, as the greatest benefits of testosterone supplementation will be seen by the diabetologist, cardiologist, GP and, most importantly, the patient. Declaration of interests Geoff Hackett is an occasional speaker for Lilly, Bayer and Boehringer Ingelheim. REFERENCES 1 Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30: Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89: Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population based study. Eur J Endocrinol 2003;149: Kupelian V, Page ST, Araujo AB, et al. Low sex hormone binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development KEY POINTS Late-onset hypogonadism or testosterone deficiency syndrome is prevalent in men with type 2 diabetes There are also links with visceral adiposity, insulin resistance, HbA 1c, and symptoms of hypogonadism such as erectile dysfunction and low sexual desire Insulin resistance and visceral obesity are established markers of cardiovascular risk Guidelines recommend that patients with symptoms of overt hypogonadism and total testosterone levels below 8nmol/l should be treated with testosterone replacement therapy, but there is no UK policy for screening at-risk populations such as those with type 2 diabetes Failure to measure testosterone results in considerable waste of resources, as response rates to phosphodiesterase type 5 inhibitors are low in men with type 2 diabetes and late-onset hypogonadism of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997;82: Hak AE, Witteman JCM, De Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 2002;87: Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93: Hackett G, Kell P, Ralph D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5: Wespes E, Amar E, Hatzichristou DG, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006;49: NICE. Type 2 diabetes: the management of type 2 diabetes. Clinical guidance 66. May Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. IJCP 2010;64: Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes; Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: NICE. Reducing the rate of premature deaths from cardiovascular disease and other smoking-related diseases. Public health guidance 15. September Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151: Haffner SM, Shaten J, Stern MP, et al. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143: Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men. Results from the Third National Health and Nutrition Survey (NHANES III). Diabetes Care 2007;30: Hackett G, Cole N, Deshpande A, et al. Biochemical hypogonadism in men with type 2 diabetes in primary care practice. Br J Diabetes Vasc Dis 2009;9: Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review TRENDS IN UROLOGY & MEN S HEALTH OCTOBER/NOVEMBER
5 26 of research and clinical experience. Int J Impot Res 2005;17: Ho CMK. Reference interval for calculated BAT using the Vermeulen equation. Ann Clin Biochem 2006;43: Home P, Mant J, Diaz J, Turner C, on behalf of the Guideline Development Group. Manage ment of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336: Wu FW, Tajar A, Beynon JM, et al. for the EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363: Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000;163: Rhoden EL, Ribeiro EP, Riedner CE, et al. Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int 2005;95: Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154: Kapoor D, Clarke S, Stanworth R, et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156: Zitzmann M, Hanisch JU, Mattern A. IPASS: Data from an ongoing study of the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism. J Men s Health 2009;6: Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30: Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009;21:24 36.
Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationGP guide to testosterone replacement therapy in men
GP guide to testosterone replacement therapy in men SPL Mike Kirby FRCP Professor Mike Kirby describes how the diagnosis and treatment of test - osterone deficiency in primary care can lead to improved
More informationAndrogen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes
Med. J. Cairo Univ., Vol. 84, No. 3, December: 341-347, 2016 www.medicaljournalofcairouniversity.net Androgen Pattern and Erectile Function in Newly Diagnosed Type 2 Diabetes AHMED I. EL-SAKKA, M.D.*;
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationTestosterone Deficiency Syndrome. Time for Proper Personalised Care
Prof Geoffrey Hackett Good Hope Hospital Sutton Coldfield Testosterone Deficiency Syndrome Time for Proper Personalised Care BSSM Testosterone Guidelines 2017 www.bssm.org.uk Recommendations Diagnosis
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationAlternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
More informationPrimary Hypogonadism In Ghanaian Men With Type 2 Diabetes Mellitus
Primary Hypogonadism In Ghanaian Men With Type 2 Diabetes Mellitus H. Asare-Anane, E.K. Ofori, F.A.Yeboah, E.A. Tagoe, S.B. Bani, A.T. Bawah, R.O Ateko Abstract-Emerging evidence links insulin resistance,
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationSexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by
More informationErectile Dysfunction and Low Testosterone: Findings in a Cohort of Barbadian Diabetic Males
Erectile Dysfunction and Low Testosterone: Findings in a Cohort of Barbadian Diabetic Males Dr. Diane Brathwaite M.B.B.S (UWI), MRCP (London), MSc Diabetes, MSc Endocrinology Clinical Coordinator The Diabetes
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationSexual dysfunction in men with diabetes
Article Sexual dysfunction in men with diabetes Lesley Mills Citation: Mills L (2015) Sexual dysfunction in men with diabetes. Journal of Diabetes Nursing 19: 332 8 Article points 1. Sexual dysfunction
More informationMen Getting Older Will Testosterone Keep Him Young?
Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and
More informationPrivate urology praxis, Bremerhaven, Germany 2. Endocrinology, VUmc, Amsterdam, The Netherlands 3
Article 167 Improvement of the Metabolic Syndrome and of Non-alcoholic Liver Steatosis upon Treatment of Hypogonadal Elderly Men with Parenteral Testosterone Undecanoate Authors A. Haider 1, L. J. G. Gooren
More informationTestosterone therapy (TTh) prevents progression from prediabetes to type 2 diabetes (T2DM) in hypogonadal: 9-year data from a registry study
Testosterone therapy (TTh) prevents progression from prediabetes to type 2 diabetes (T2DM) in hypogonadal: 9-year data from a registry study F Saad 1,2, KS Haider 3, A Haider 3 1 Global Medical Affairs
More informationEvery obese male with type 2 diabetes should be screened for hypogonadism
Every obese male with type 2 diabetes should be screened for hypogonadism FOR Professor T Hugh Jones Consultant Physician & Endocrinologist, Robert Hague Centre for Diabetes and Endocrinology, Barnsley
More informationGUIDELINES ON MALE HYPOGONADISM
GUIDELINES ON MALE HYPOGONADISM (Text update March 2015) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch, M. Punab Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationMEN S HEALTH. Selected topics in. Erectile dysfunction Gynaecomastia Late-onset hypogonadism Delayed puberty in males
Selected topics in MEN S HEALTH www.bpac.org.nz keyword: menshealth Erectile dysfunction Gynaecomastia Late-onset hypogonadism Delayed puberty in males 2 September 2010 best tests Erectile dysfunction
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erectile_dysfunction 01/01/2019 n/a 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description of Procedure
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationThe Centre for Men s Health
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
More information9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont)
Faculty Testosterone Replacement Therapies: Mitigating Cardiometabolic Risks Associated with Hypogonadism Pamela Ellsworth, MD Professor of Urology University of Massachusetts Medical School Vice Chair,
More informationERECTILE DYSFUNCTION DIAGNOSIS
ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz
More informationInfluence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency
Janjgava et al. European Journal of Medical Research 2014, 19:56 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access Influence of testosterone replacement therapy on metabolic disorders in male patients
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationdepression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function
International Journal of Advances in Medicine Jakka NR et al. Int J Adv Med. 2017 Aug;4(4):1106-1110 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20173241
More informationPresent and future association between obesity and hypogonadism in Italian male
ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationTESTOSTERONE CONCENTRATIONS IN DIABETIC AND NON-DIABETIC OBESE MEN
Diabetes Care Publish Ahead of Print, published online March 3, 2010 TESTOSTERONE CONCENTRATIONS IN DIABETIC AND NON-DIABETIC OBESE MEN Sandeep Dhindsa, MD Michael G. Miller, Pharm.D. Cecilia L McWhirter*,
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationClinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes. Correlations with bioavailable testosterone and visceral adiposity
Pathophysiology/Complications O R I G I N A L A R T I C L E Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes Correlations with bioavailable testosterone and visceral adiposity
More informationUK policy statements on testosterone deficiency
Received: 4 March 2016 Revised: 24 August 2016 Accepted: 27 September 2016 DOI: 10.1111/ijcp.12901 CONSENSUS UK policy statements on testosterone deficiency Geoffrey Hackett 1,2 Michael Kirby 3,4 David
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationRELATIONSHIP BETWEEN BMI, TOTAL TESTOSTERONE, SEX HORMONE-BINDING-GLOBULIN, LEPTIN, INSULIN AND INSULIN RESISTANCE IN OBESE MEN
Archives of Andrology, 52:355 361, 2006 Copyright # Informa Healthcare ISSN: 0148-5016 print/1521-0375 online DOI: 10.1080/01485010600692017 RELATIONSHIP BETWEEN BMI, TOTAL TESTOSTERONE, SEX HORMONE-BINDING-GLOBULIN,
More informationEFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationTestosterone Concentrations in Diabetic and Nondiabetic Obese Men
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Testosterone Concentrations in Diabetic and Nondiabetic Obese Men SANDEEP DHINDSA, MD 1 MICHAEL G. MILLER, PHARMD 1 CECILIA L. MCWHIRTER,
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationHORMONE THERAPY IN AGING MALE ATHLETES
DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the
More informationMale Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.
Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology
More informationType 2 Diabetes and Testosterone Therapy
Review Article pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health Published online July 17, 2018 https://doi.org/10.5534/wjmh.180027 Type 2 Diabetes and Testosterone Therapy Geoffrey Hackett Department
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationR. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga and Tobias S. K ohler
Sexual Function/Infertility Validity of Midday Total Testosterone Levels in Older Men with Erectile Dysfunction R. Charles Welliver, Jr.,* Herbert J. Wiser, Robert E. Brannigan, Kendall Feia, Manoj Monga
More informationResults: Statistical analysis of the results showed an inverse correlation between the BMI and serum testosterone.
Original Article Obesity is an independent risk factor for low serum testosterone in adult males Mohamad Habous MD, Alaa Tealab MD, Mohamed Ali MD, Amir Abdel Raheem MD, David Ralph MD, Saleh Binsaleh
More informationObesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes
Obesity and Testosterone Levels in Ghanaian Men With Type 2 Diabetes Henry Asare-Anane, PhD, Emmanuel Ofori, MPhil, Yeboah Agyemang, PhD, Sylvester Oppong, MBChB, PhD, Emmanuel Tagoe, MPhil, Simon Bani,
More informationLong-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function
Original Article pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health Published online Sep 12, 2018 https://doi.org/10.5534/wjmh.180052m Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated
More informationChapter 29: Male sexual dysfunction in type 2 diabetes
South African Family Practice 08; 60():6-0 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND.0] http://creativecommons.org/licenses/by-nc-nd/.0 S Afr Fam Pract
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More information10 Novel Testosterone Formulations and Dosing: Potential Impact on Treatment and Outcomes Ajay Nehra, MD
VOLUME 1 NUMBER 1 MAY 30, 2008 1 Letter From the Co-Chairs Glenn R. Cunningham, MD, and Ridwan Shabsigh, MD 2 CME Accreditation Information 4 Introduction 4 Epidemiology of Hypogonadism Glenn R. Cunningham,
More informationE pidemiological studies have reported
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Sex Hormone Binding Globulin, but Not Testosterone, Is Associated Prospectively and Independently With Incident Metabolic Syndrome in Men
More informationErectile dysfunction in general medicine
CLINICAL PRACTICE Clinical Medicine 2013, Vol 13, No 2: 136 40 ABSTRACT Erectile dysfunction (ED) affects millions of men worldwide with implications that go far beyond sexual activity. ED is now recognised
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationA USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW
A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW 1. Why men need to know more Good health is vital for a happy and full life. But, with work and family responsibilities, men often overlook their own health
More informationMale hypogonadism & testosterone replacement therapy
Male hypogonadism & testosterone replacement therapy Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported
More informationL ow serum testosterone is common in
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) T. HUGH
More informationErectile Dysfunction, Cardiovascular Risk and
Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationOutcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
More informationMetastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942
Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years
More informationPrevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease
Original Article Prevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease S. V. Madhu, M. Aslam, A. J. Aiman, A. Siddiqui, S. Dwivedi Department of
More informationLower levels sex hormone-binding globulin independently associated with metabolic syndrome in pre-elderly and elderly men in China
Journal of Geriatric Cardiology (2013) 10: 28 33 2013 JGC All rights reserved; www.jgc301.com Research Article Open Access Lower levels sex hormone-binding globulin independently associated with metabolic
More informationLate Onset Hypogonadism. Toh Charng Chee Hospital Selayang
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
More informationAndropause state of the art 2015 and review of selected aspects
DOI: 10.5114/pm.2015.49998 Prz Menopauzalny 2015; 14(1): 1-6 Featured paper Andropause state of the art 2015 and review of selected aspects Grzegorz Jakiel 1, Marta Makara-Studzińska 2, Michał Ciebiera
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationTestosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?
REVIEW ARTICLE Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? M. M. Miner, 1 A. D. Seftel 2 doi: 10.1111/j.1742-1241.2007.01317.x 1 Department
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationREVIEW Obesity, low testosterone levels and erectile dysfunction
(2009) 21, 89 98 & 2009 Nature Publishing Group All rights reserved 0955-9930/09 $32.00 www.nature.com/ijir REVIEW Obesity, low testosterone levels and erectile dysfunction M Diaz-Arjonilla 1, M Schwarcz
More informationTestosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014
Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationThe Sexual Medicine Society of North. Adult-Onset Hypogonadism SPECIAL ARTICLE
SPECIAL ARTICLE Adult-Onset Hypogonadism Mohit Khera, MD, MBA, MPH; Gregory A. Broderick, MD; Culley C. Carson III, MD; Adrian S. Dobs, MD, MHS; Martha M. Faraday, PhD; Irwin Goldstein, MD; Lawrence S.
More informationClomiphene citrate treatment for late onset hypogonadism: rise and fall
ORIGINAL ARTICLE Vol. 42 (x): 2016 July 4.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2016.0112 Clomiphene citrate treatment for late onset hypogonadism: rise and fall Marcelo Marconi 1, Renato Souper
More informationTHE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION
THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION Aksam A. Yassin MD PhD EdD FEBU Professor of Urology & Human Sexuality Institute of Urology & Andrology, Segeberger
More informationStatin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Diabetes Care Publish Ahead of Print, published online December 29, 2008 Statins associated with lower total testosterone Statin therapy is associated with lower total but not bioavailable or free testosterone
More informationTestosterone Deficiency with Erectile Dysfunction in Mongolian Men
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2013 August 31(2): 170-175 http://dx.doi.org/10.5534/wjmh.2013.31.2.170 Original Article Testosterone Deficiency with Erectile Dysfunction in Mongolian
More informationHypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl
Sexual Medicine Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dl Jason M. Scovell, Ranjith Ramasamy, Nathan Wilken, Jason R. Kovac and Larry I. Lipshultz
More informationStatin Therapy and Serum Testosterone in Men with Type 2 Diabetes
The Egyptian Journal of Hospital Medicine (June 2010) Vol., 39: 281-287 Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes Abstract OBJECTIVE Mohammed Fakhraldeen*, Huseen Saad Mostafa**
More informationAndrogen deficiency in men has attracted much
Journal of Andrology, Vol. 33, No. 5, September/October 2012 Copyright E American Society of Andrology The Comparison of the Aging Male Symptoms (AMS) Scale and Androgen Deficiency in the Aging Male (ADAM)
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More information